The xeroderma pigmentosum variant (XP-V) is one of the most common forms of this cancer-prone syndrome. XP groups A through G are characterized by defective nucleotide excision repair, whereas the XP-V phenotype is pro®cient in this pathway. The XPV gene encodes DNA polymerase Z, which catalyzes an accurate translesion synthesis, indicating that the XPV gene contributes tumor suppression in normal individuals. Here we describe the genomic structure and chromosomal localization of the XPV gene, which includes 11 exons covering the entire coding sequence, lacks a TATA sequence in the upstream region of the transcriptioninitiation, and is located at the chromosome band 6p21.1-6p12. Analyses of patient-derived XP-V cell lines strongly suggested that three of four cell lines carried homozygous mutations in the XPV gene. The fourth cell line, XP1RO, carried heterozygous point mutations in the XPV gene, one of which was located at the splice acceptor site of exon 2, resulting in the omission of exon 2 from the mature mRNA. These ®ndings provide a basis for diagnosis and therapy of XP-V patients. Oncogene (2000) 19, 4721 ± 4728.
Introduction
Xeroderma pigmentosum (XP) is an autosomal recessive human disease characterized by sunlight sensitivity, cutaneous and ocular deterioration, and premature malignant skin neoplasms on sun exposure. XP has been classi®ed into eight complementation groups, XP-A to XP-G and XP-V. Cells from XP-A to XP-G patients are de®cient in nucleotide excision repair (NER) which is the most versatile and ubiquitous mechanism for DNA repair operating to remove many types of lesions, including ultraviolet light (UV)-induced cyclobutane pyrimidine dimers (CPDs) and (6 ± 4) photoproducts (Friedberg et al., 1995) . In contrast, cells from XP-V, which comprises a substantial minority (approximately 20%) of XP patients, are normal in NER (Cleaver, 1972) but are defective in replication after UV-irradiation (Lehmann et al., 1975) and demonstrate hypermutability after exposure to UV-irradiation or DNA damage agents (Maher et al., 1976; Wang et al., 1991 Wang et al., , 1993 Misra and Vos, 1993; Waters et al., 1993) . Some groups reported that cell-free extracts from XP-V cells lacked abilities to replicate DNA past CPDs and chemical agentinduced lesions (Carty et al., 1996; Cordeiro-Stone et al., 1997; Ensch-Simon et al., 1998; Svoboda et al., 1998; Cordonnier et al., 1999) . Using an improved cellfree DNA replication system, we have puri®ed an XP-V correcting protein from HeLa cells (Masutani et al., 1999a) and cloned the XPV cDNA (Masutani et al., 1999b) . The XPV gene was found to be a human homologue of Saccharomyces cerevisiae RAD30 (Masutani et al., 1999b; Johnson et al., 1999) and encodes DNA polymerase Z which catalyzes translesion synthesis in an accurate manner by incorporating dAMP opposite thymine residues of a cyclobutane thymine dimer (Masutani et al., 1999a) . In addition to XPV, human cells have been shown to have some DNA polymerases potentially involved in the translesion synthesis such as human homologues of E. coli DinB (Gerlach et al., 1999; Ogi et al., 1999; Johnson et al., 2000) , S. cerevisiae Rev3 (Gibbs et al., 1998; Xiao et al., 1998; Lin et al., 1999a) and Rev1 (Lin et al., 1999b; Gibbs et al., 2000) and another human homologue of RAD30 (McDonald et al., 1999) . Among them, however, XPV is the only gene whose product is known to catalyze accurate translesion synthesis and is responsible for the human genetic disease.
In this study, we present the genomic structure and characterization of the XPV gene, including transcription-initiation sites and putative promoter sequences, and chromosomal mapping. We also designed sets of PCR primers to amplify speci®c regions of the XPV gene from genomic DNA, and examined mutations in these regions by direct sequencing of the PCR products. These analyses will facilitate the genetic diagnosis of XP-V patients as well as other studies of basic sciences. and sequenced to identify the exon/intron boundaries and the 5' upstream region. Intron lengths were determined by PCR with the intron-spanning primers shown in Figure 1a and Table 1 , using the clone 71N21 as a template. We identi®ed eleven exons, spanning about 40 kbp, that contained the entire coding sequence of the XPV cDNA (Figure 1b) . The ®rst ATG codon for initiation of translation was included in the second exon. Exon 11 contained the termination codon followed by 661 bp of 3'-untranslated sequence. We have previously identi®ed seven regions, denoted A through G in Figure 1b , of amino acid sequence conservation among polymerase Zrelated proteins, including E. coli DinB and UmuC, S. cerevisiae Rad30 and Rev1, and related proteins from S. pombe, C. elegans and A. thaliana (Masutani et al., 1999b) . Although the regions C and E were encoded by two exons (exons 3 and 4), and three exons (exons 5, 6, and 7) respectively, the other conserved regions were essentially encoded by single exons. Such genomic organization, together with the observed level of amino acid sequence conservation in this protein family, indicates that these regions represent functional units which are essential to the activity of the gene product. The genomic sequences of the exon/intron boundaries are shown in Table 2 . Of the 11 splice donor/acceptor sites, 10 contained consensus GT/AG dinucleotides; only the splice donor site in exon 11, which had the sequence CT, varied from the consensus pattern.
Transcription initiation site
Transcription initiation sites were determined by RNase protection assay ( Figure 2 ). As the sites were expected to be close to the 5' end of the cloned cDNA on the basis of 5'-RACE experiments (data not shown), the sequence spanned by primers A and B (Figure 2a ) was examined. An anti-sense RNA probe which consisted of the 193 nucleotides (nt) of the XPV gene between primers and A and B, plus 60 nt from the plasmid vector, was prepared and hybridized with total RNA from HeLa cells (Figure 2b ). After digestion with RNase A and T1, the protected RNA fragments were separated on a sequencing gel. As shown in Figure 2b , the products protected by HeLa RNA were not observed when the probe was mock-treated in the absence of HeLa RNA (compare lanes 5 and 6 with 8).
Comparison with anti-sense strand sequencing ladders (lanes 1 ± 4) revealed that the major 117 nt protected product corresponded to a cytosine residue which we therefore designated +1 (Figure 2a ). Minor bands corresponding to thymines at +3 and 75 were also detected. The XPV gene lacked a TATA sequence in the region upstream of the transcription-initiation sites. However, a sequence similar to the initiator element (Inr) of the terminal deoxytransferase gene, which was reported to be responsible for specifying a precise initiation site for transcription in TATA-less promoters (Weis and Reinberg, 1992; Zenzie-Gregory et al., 1992; Javahery et al., 1994; Smale, 1997) , was found in the (Masutani et al., 1999b) region +1 to +13. The upstream region was GC rich (76% in the sequences between +1 and 7270) and contained ®ve sequences matching the canonical Sp1-binding site sequence (Jones et al., 1988; Mitchell and Tjian, 1989) . These characteristics suggest that the XPV gene has a promoter typical of housekeeping genes. We also found two sequences similar to an E2F-binding site at 7174 to 7167 and +162 to +155, although both contained two mismatches to the consensus.
Chromosomal localization
Chromosomal localization of the XPV gene was ®rst examined by screening a human/rodent somatic cell hybrid mapping panel 2 (Coriell Cell Repositories, NJ, USA), using PCR with primers speci®c to the XPV gene. In this analysis, speci®c products were obtained when chromosome 6 was used as a template for PCR (data not shown). We also detected a processed XPV pseudogene on chromosome 2 both by Southern analysis using hybrid panel DNAs and direct sequencing of PCR products from human chromosome 2. In addition, we identi®ed four YAC clones (683F8, 717D5, 810D11 and 963C6) containing the XPV gene from CEPH megaYAC library by PCR screening. Two of them (717D5 and 810D11) commonly contained three chromosome 6-derived STSs (i.e., D6S271, WI-6878 and WI-8795), and the clone 810D11 was mapped to 6p21 by previous¯uorescent in situ hybridization (FISH) analysis (Bray-Ward et al., 1996) . Finally, we performed FISH analysis with normal metaphase chromosomes, in which speci®c signals were detected on the short arms of chromosome band 6p21.1-6p12 ( Figure 3 ). In the current UniGene database, the EST coding XPV product (DNA polymerase Z) was detected as H96387 and was mapped in chromosome 6 between D6S1616-D6S427 (59.6 ± 73.9 cM) in which the marker WI-8795 locates by radiation hybrid mapping (http://www.ncbi.nlm.nih.gov/genemap98). This is also consistent with our results.
Mutations in patients
One of the most important potential applications of the XPV gene sequence is in diagnosis. For this purpose, we designed sets of PCR primers ( Figure 1a and Table 1 ) to amplify speci®c regions of the XPV gene from genomic DNA, and examined mutations in these regions by direct sequencing of the PCR products. We have previously identi®ed mutations in XPV cDNAs from the ®ve XP-V cell lines XP1RO, XP30RO, XP2SA, XP7TA, and (Masutani et al., 1999b) . Analysis of these cDNAs showed that XP1RO is a compound heterozygote with a 141 nt deletion in the highly expressed allele and a point mutation on the minor allele. Genomic DNA analysis revealed a G to C transversion at the splice acceptor site of exon 2 and a G to A transition in exon 8 (Figure 4a and b) . The former mutation is predicted to cause the removal of exon 2 by splicing during mRNA mutation (Figure 4c ), resulting in small transcripts from which the 141 nt exon 2 is absent. A second mutation in the XP1RO genome corresponded to the point mutation identi®ed in cDNA from the minor allele, and is predicted to cause premature termination of the protein. We have also found mutations in cDNAs derived from dominant alleles in the other XP-V cell lines. However, the cDNA analyses could not exclude the possibility that these cell lines had silent or weakly expressed alleles in addition to the alleles detected, because except for XP4BE, XPV mRNA expression levels were lower in these cell lines than in normal cells. Genomic DNA analysis revealed the following homozygous mutations: a 13 nt deletion in exon 2, a G to T transversion in exon 8, and a 2 nt deletion in exon 5 in XP30R0, XP2SA and XP7TA cells, respectively ( Figure  4d ± f). From these results we conclude that the patients from which these cell lines were derived had homozygous mutations in the XPV gene, meaning that they had no wild-type XPV gene, although the possibility remains that they carried deletions in one of the two copies of chromosome 6. 
Discussion
In this paper, we provide the structural organization and characterization of the human XPV gene. We designed primers for PCR-ampli®cation and sequencing of the XPV genomic DNA. This allows for improved mutation screening of XPV for putative XP-V patients, particularly where no mRNA was available. The promoter sequence of the XPV gene was found to have typical characteristics of mammalian housekeeping gene promoters such as high GC contents, including Sp1-binding sequence and lack of a TATA sequence. Immediately downstream of the major transcription-initiation site proposed by RNase protection assay, 11 of 14 nucleotides matched the TATAless initiator signal of the terminal deoxytransferase (TdT) gene (Javahery et al., 1994) . Therefore, initiation of transcription of the human XPV gene may occur by the mechanism similar to that of TdT gene. The human XPV gene had two similar sequences to E2F-binding site between 71118 and +232 ( Figure 3 ). E2F is known to play crucial roles in the transactivation of genes involved in DNA replication (Helin, 1998) . As the expression of mouse XPV gene was stimulated by the serum-induced proliferation of Swiss 3T3 cells (Yamada et al., 2000) , these sequences might be involved in the regulation of the cell cycle-dependent expression of the gene.
Fluorescence in situ hybridization mapped the XPV gene to the chromosome band 6p21.1-6p12. It is possible that genes in the neighborhood are responsible for some phenotypes of the patients if they have large deletions of the genome, although we have not found out such patients yet. Chromosomal aberrations at this locus have been reported in association with a variety of cancers (Mitelman et al., 1997) and the XPV gene product, DNA polymerase Z, is responsible for accurate translesion synthesis but can also function as a highly mutagenic DNA polymerase in the replication of undamaged DNA (Matsuda et al., 2000) . Thus, it is possible that inactivation or unregulated expression of the XPV gene caused by the chromosomal translocation might be responsible for some of these cancers.
We provide the mutation analysis of the XPV genomic DNA from four XP-V cell lines, XP1RO, XP30RO, XP2SA, and XP7TA. The genomic DNA analysis strongly suggested that these cell lines except for XP1RO have homozygous mutations, and XP1RO have heterozygous mutations, one of which is a splice mutation on the major allele. With respect to XPV transcriptional level, a striking reduction in the defective mRNAs was observed in XP2SA and XP7TA, and slight reduction in those was observed in XP1RO and XP3RO cell lines, compared with the transcriptional level of intact mRNA in cells of normal subjects, as described previously (Masutani et al., 1999b) . We also examined sequences in the 5'-upstream region (71080 to +90) of the XPV gene from XP1RO, XP30RO, XP2SA and XP7TA cells. However, we found no mutations in the potential regulatory region for mRNA expression in these XP-V cells. Together with the decreased levels of XPV mRNA in these cells, the mutations found in these cells might aect the stability of the mRNA, since it has been postulated that early nonsense codon-mediated mRNAs are degraded preferentially by cellular 5' to 3' exonuclease, preceded by poly(A) shortening (Lim and Maquat, 1992; Muhlrad and Parker, 1994) .
It is sometimes dicult to distinguish XP-V patients from patients with mild disease belonging to another XP group, mainly due to the relatively low sensitivity of XP-V cells to ultraviolet light and the lack of simple methods such as unscheduled DNA synthesis to test for speci®c XP-related cellular defects. However, it is important to diagnose these patients correctly, because XP-V patients have defects in a dierent cellular mechanism from other groups of XP: XP-V is characterized by a defect in translesion synthesis whereas the other forms of XP show defects in nucleotide excision repair. It will now be possible to diagnose XP-V patients more rapidly and precisely on the basis of the genomic structure and/or chromosomal localization of the XPV gene.
Materials and methods

Determination of the XPV genomic structure
A PAC (P1-derived arti®cial chromosome) human genomic DNA library (Genome Systems Inc.) was screened with PCR using the gene-speci®c primers 54L3C2F (5'-GAG ATG TAA AAA TTC ATC CTA CCA GAG-3') and 54L3C2R (5'-TGT GAA GAA AAT GAC TTG TTC AAG GCC-3') and successive hybridization with a labeled cDNA probe. A positive PAC clone, 71N21, was identi®ed, and puri®ed 71N21 DNA was digested with several restriction enzymes. The resulting fragments were subjected to Southern blot analyses with XPV cDNA as a probe. The positive (XPVhybridizing) fragments produced by EcoRI digestion were subcloned into pBluescript II SK(+) plasmid and then sequenced with an automated DNA-sequence analyser (Applied Biosystems PRISM310). Exon-intron boundaries were determined by comparison of this genomic sequence with the XPV cDNA.
To determine intron lengths, we designed PCR primers to match the XPV cDNA sequences and performed intronspanning PCR reactions using the PAC clone 71N21 as template. The standard PCR mixture consisted of 2 mg 71N21 DNA, 10 pmol of each primer, 2.5 mM MgCl 2 , 250 mM of each dNTP, 16LA Taq buer, and 1 unit of LA Taq DNA polymerase (Takara) in a ®nal volume of 20 ml. Ampli®cation was performed using the primer pairs shown in Figure 2 , with a two-step PCR program which consisted of six cycles of denaturation at 988C for 20 s and extension at 688C for 15 min, followed by six cycles each of 988C for 20 s/668C for 15 min, 988C for 20 s/648C for 15 min and 988C for 20 s/ 628C for 15 min, followed by incubation at 728C for 10 min. The only exception to this protocol was the ampli®cation of the intron between exons 4 and 5. To determine the distance between exons 4 and 5, PCR ampli®cation (with the primer pair a6 and b6) was performed using a three-step PCR program consisting of 30 cycles of denaturation at 948C for 15 s, annealing at 558C for 30 s and extension at 688C for 15 min, followed by incubation at 728C for 10 min. In order to verify exon/intron boundaries, PCR products were separated by electrophoresis on agarose gels, puri®ed with the QIAquick Gel Extraction kit (QIAGEN) and sequenced with an automated DNA sequencer analyser as described above, using the same primers for sequencing as for the original ampli®cation.
RNase protection assay
Total RNA was isolated from HeLa cells using Isogen (Nippon gene) according to the manufacturer's instructions.
A 307 bp fragment of the 5' upstream region of the XPV gene was ampli®ed by PCR using the plasmid containing the 71N21-derived 12 kb fragment of 5' upstream sequence of the XPV gene as template and the primers A (5'-AGG AGC GTT AGC AGC AAC TC-3') and B (5'-TTC CCT GTG ACG ACG GAG AAA C-3') shown in Figure 2 , subcloned into the pGEM-T easy vector (Promega) and veri®ed by DNA sequencing. The resulting plasmid was linearized by BlnI digestion and used as a template for preparation of an anti-sense RNA probe. The RNA probe was synthesized by T7 RNA polymerase (Promega) in the presence of [a-32 P]CTP using 1 mg of the linearized DNA template according to the manufacturer's instructions.
Ten mg of total RNA was hybridized with the anti-sense RNA probe (5610 5 cpm) at 508C or 558C for 18 h in hybridization buer containing 80% formamide, 0.4 M NaCl, 40 mM PIPES [piperazine-N, N'-bis (2-ethansulfonic acid), pH 6.4], and 1 mM EDTA. Nonhybridizing RNA was digested with 40 mg/ml RNase A and 2 mg/ml RNase T1 at 308C in RNA digestion buer containing 10 mM Tris-HCl (pH 7.5), 5 mM EDTA and 0.3 M NaCl, and then incubated with proteinase K at 378C. The protected RNA fragments were heat-denatured and analysed on 8% polyacrylamide gels containing 7M urea together with dideoxynucleotide chain termination sequence ladders derived from the BlnI-digested plasmid DNA (Amersham Life Science sequencing kit).
Fluorescent in situ hybridization (FISH) analysis
An R-banding method (Takahashi et al., 1990 ) and a cooled digital imaging system were used to determine the physical location of the human XPV gene in metaphase chromosomes. The preparation of chromosome spreads, probe labeling, and in situ hybridization were performed according to Okumura et al. (1995) . PAC DNA (the clone 71N21 containing the human XPV gene) was biotinylated by nick-translation with biotin-16-dUTP (Boehringer Mannheim) and hybridized to R-banded chromosome spreads from a normal human male lymphocyte in the presence of human COT-1 DNA (Gibco ± BRL) as a competitor. Detection of hybridized probes on banded chromosomes was carried out using¯uorescein isothiocyanate (FITC)-conjugated avidin (Boehringer Mannheim). Following counterstaining with 0.2 mg/ml propidium iodide, chromosomes were photographed using a Leica DMR HC epi¯uorescence microscope equipped with a cooled CCD camera (Photometrics MicroMax-1317K). FITC and propidium iodide were detected as green and red colors, respectively. More than 20 metaphase spreads were examined and comparison between the¯uorescent signals and the banding patterns of the chromosomes indicated that the physical location of the human XPV gene was on chromosome bands 6p12-p21.1.
Mutation analysis of XPV genomic DNA in XP-V cells
Genomic DNA was prepared from the four XP-V cell lines XP1RO, XP30RO, XP7TA and XP2SA using a QIAGEN Blood and Cell Culture DNA Midi Kit according to the manufacturer's instructions. Using 200 ng of genomic DNA as a template, ®rst-round PCR was performed with the primers indicated in the left-hand panel of Table 1 , using the standard PCR mixture and two-step cycling program described above. Second-round PCR was performed under the same conditions except for an extension time of 1 min, using the product of the ®rst PCR (1 ml) as a template and the primers indicated in the right-hand panel of Table 1 . The PCR products were puri®ed by agarose gel electrophoresis and subjected to direct sequencing with an automated DNA sequence analyser as described above. Mutations in exon 8 from XP1RO (secondary allele) and XP2SA cells, and a mutation in exon 5 from XP7TA, were examined by sequencing of PCR products ampli®ed from genomic DNA with primers a9 (5'-TCC AGA GTC ATT TTG GGG-3') and b9 (5'-GGT TTT GGG TAG TTG CCT G-3') and a6 (5'-GTT GCC AAG CAC TTA CAT TGA AGG-3') and b6 (5'-TGA AAA CCA GTC TCC CTC TCT ATG G-3'), respectively. PCR ampli®cation of exons 8 and 5 was performed with the two-step and three-step programs described above, respectively.
Accession numbers
Sequence data from this article have been deposited with the EMBL/GenBank Data Libraries under Accession Nos. AB037998-AB038008.
